Janus Henderson Group PLC Zentalis Pharmaceuticals, Inc. Transaction History

Janus Henderson Group PLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$4.09 - $16.13 $1,165 - $4,597	-285 Reduced 1.33%	21,172 $86,000
Q1 2024 May 15, 2024	BUY	$10.83 - $16.49 $21 - $32	2 Added 0.01%	21,457 $338,000
Q4 2023 Feb 14, 2024	SELL	$9.84 - $20.13 $432 - $885	-44 Reduced 0.2%	21,455 $325,000
Q3 2023 Nov 14, 2023	BUY	$19.63 - $28.29 $215 - $311	11 Added 0.05%	21,499 $431,000
Q2 2023 Aug 14, 2023	BUY	$17.41 - $30.05 $626 - $1,081	36 Added 0.17%	21,488 $606,000
Q1 2023 May 15, 2023	BUY	$16.14 - $24.94 $177,523 - $274,315	10,999 Added 105.22%	21,452 $368,000
Q4 2022 Feb 14, 2023	BUY	$18.07 - $25.6 $18 - $25	1 Added 0.01%	10,453 $210,000
Q2 2022 Aug 15, 2022	BUY	$17.91 - $52.25 $187,195 - $546,117	10,452 New	10,452 $295,000

136

68.4M

61.8K

6.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $223M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.